[HTML][HTML] Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics
K Lazaridis, SJ Tzartos - Frontiers in immunology, 2020 - frontiersin.org
Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and
fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by …
fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by …
Myasthenia gravis—autoantibody characteristics and their implications for therapy
NE Gilhus, GO Skeie, F Romi, K Lazaridis… - Nature reviews …, 2016 - nature.com
Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies that target the
neuromuscular junction, leading to muscle weakness and fatigability. Currently available …
neuromuscular junction, leading to muscle weakness and fatigability. Currently available …
[HTML][HTML] Myasthenia gravis: a clinical-immunological update
Myasthenia gravis (MG) is the archetypic disorder of both the neuromuscular junction and
autoantibody-mediated disease. In most patients, IgG1-dominant antibodies to acetylcholine …
autoantibody-mediated disease. In most patients, IgG1-dominant antibodies to acetylcholine …
[HTML][HTML] Myasthenia gravis: autoantibody specificities and their role in MG management
K Lazaridis, SJ Tzartos - Frontiers in neurology, 2020 - frontiersin.org
Myasthenia gravis (MG) is the most common autoimmune disorder affecting the
neuromuscular junction, characterized by skeletal muscle weakness and fatigability. It is …
neuromuscular junction, characterized by skeletal muscle weakness and fatigability. It is …
[HTML][HTML] Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
AG Vakrakou, E Karachaliou, E Chroni… - Frontiers in …, 2023 - frontiersin.org
Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-
mediated disease characterized by predominantly focal muscle weakness (neck, facial, and …
mediated disease characterized by predominantly focal muscle weakness (neck, facial, and …
Myasthenia gravis: from autoantibodies to therapy
R Mantegazza, P Bernasconi… - Current Opinion in …, 2018 - journals.lww.com
Myasthenia gravis: from autoantibodies to therapy : Current Opinion in Neurology
Myasthenia gravis: from autoantibodies to therapy : Current Opinion in Neurology Log in or …
Myasthenia gravis: from autoantibodies to therapy : Current Opinion in Neurology Log in or …
[HTML][HTML] Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis
Myasthenia gravis (MG) is a B cell–mediated autoimmune disorder of neuromuscular
transmission. Pathogenic autoantibodies to muscle-specific tyrosine kinase (MuSK) can be …
transmission. Pathogenic autoantibodies to muscle-specific tyrosine kinase (MuSK) can be …
Diagnosis and treatment of myasthenia gravis
R Mantegazza, P Cavalcante - Current opinion in rheumatology, 2019 - journals.lww.com
CBAs can lead to a significant reduction of seronegative patients, improving myasthenia
gravis diagnostic process. New biological drugs offer innovative approaches to treat …
gravis diagnostic process. New biological drugs offer innovative approaches to treat …
Pathophysiology and immunological profile of myasthenia gravis and its subgroups
F Romi, Y Hong, NE Gilhus - Current opinion in immunology, 2017 - Elsevier
Highlights•Myasthenia gravis is an antibody-mediated disease.•Antibodies in myasthenia
gravis are directed against several postsynaptic neuromuscular proteins and …
gravis are directed against several postsynaptic neuromuscular proteins and …
Titin antibodies in “seronegative” myasthenia gravis—a new role for an old antigen
C Stergiou, K Lazaridis, V Zouvelou, J Tzartos… - Journal of …, 2016 - Elsevier
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies targeting the
neuromuscular junction of skeletal muscles. Triple-seronegative MG (tSN-MG, without …
neuromuscular junction of skeletal muscles. Triple-seronegative MG (tSN-MG, without …